Repligen (NASDAQ:RGEN) Price Target Raised to $170.00 at Canaccord Genuity Group
Repligen (NASDAQ:RGEN – Get Free Report) had its target price increased by analysts at Canaccord Genuity Group from $165.00 to $170.00 in a report released on Friday,Benzinga reports. The firm currently has a “hold” rating on the biotechnology company’s stock. Canaccord Genuity Group’s target price would suggest a potential upside of 6.92% from the stock’s […]
Repligen (NASDAQ:RGEN – Get Free Report) had its target price increased by analysts at Canaccord Genuity Group from $165.00 to $170.00 in a report released on Friday,Benzinga reports. The firm currently has a “hold” rating on the biotechnology company’s stock. Canaccord Genuity Group’s target price would suggest a potential upside of 6.92% from the stock’s […]
